Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

for
Breast Cancer, Metastatic Breast Cancer
Location: Chapel Hill NC, Birmingham AL
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06855654

Recruiting

IMPACT: IMplementation of Physical Activity for Children and Adolescents on Treatment

for
Pediatric Cancer, Pediatric Hematology
Location: Edmonton, Calgary
Sponsor: University of Calgary

Sex: All

Age: 5 - 18

Code: NCT04956133

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Colorectal Cancer
Location: New Brunswick NJ, Toronto, Atlanta GA, Ann Arbor MI,
Sponsor: Vividion Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06004245

Phase 1, Recruiting

Cognitive Rehabilitation Following Breast Cancer Treatment

for
Breast Cancer Female
Location: Columbia MO
Sponsor: University of Missouri-Columbia

Sex: Female

Age: 20 - 70+

Code: NCT06545045

Recruiting

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

for
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Sex: Female

Age: 18+

Code: NCT04516447

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

for
Advanced Refractory Solid Tumors,
Location: New Haven CT, Ohio City OH, Michigan Center MI,
Sponsor: Cosmo Technologies Ltd

Sex: All

Age: 18+

Code: NCT03863145

Early Phase 1, Recruiting

COAST Therapy in Advanced Solid Tumors and Prostate Cancer

for
Prostate Cancer Recurrent, Solid Tumor, Adult
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT05036226

Phase 1, Phase 2, Recruiting

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

for
Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer,
Location: Boston MA, New Haven CT, The Bronx NY,
Sponsor: Ana C Garrido-Castro, MD

Sex: All

Age: 18+

Code: NCT06533826

Phase 2, Recruiting

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

for
Breast Cancer
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: Female

Age: 20 - 70+

Code: NCT06878547

Recruiting

A Multicenter Breast Cancer Biospecimen Registry

for
Breast Cancer
Location: Dallas TX, Redding CA
Sponsor: Luminist, Inc.

Sex: Female

Age: 40+

Code: NCT02712645

Recruiting

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

for
Cancer
Location: West Covina CA
Sponsor: Oeyama-Moto Cancer Research Foundation

Sex: All

Age: 18 - 70+

Code: NCT02340845

Phase 2, Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: Lake Success NY, New York NY, Nashville TN, Westwood KS,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06695845

Phase 2, Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

for
Breast Cancer
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18+

Code: NCT03321045

Early Phase 1, Recruiting

FOCUS for Pediatric Sickle Cell Disease and Cancer

for
Pediatric Cancer, Sickle Cell Disease, Quality of Life,
Location: Atlanta GA
Sponsor: Georgia State University

Sex: All

Age: 12 - 18

Code: NCT04075877

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for
Metastatic Breast Cancer
Location: Boston MA, New York NY, New Brunswick NJ, Montreal,
Sponsor: LeonaBio

Sex: All

Age: 18+

Code: NCT05696626

Phase 3, Recruiting

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

for
Breast Atypical Ductal Hyperplasia,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT05178498

Recruiting

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

for
Breast Cancer, Metastatic Triple-Negative Breast Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05570253

Phase 2, Recruiting

QTX3034 in Patients With KRAS G12D Mutation

for
Solid Tumors
Location: New Haven CT, The Bronx NY, New York NY, Fairfax VA,
Sponsor: Quanta Therapeutics

Sex: All

Age: 18+

Code: NCT06227377

Phase 1, Recruiting

A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

for
Cancer: Recurrent and/or Metastatic Solid Tumours
Location: Edmonton
Sponsor: PharmaMatrix Holdings Ltd

Sex: All

Age: 18+

Code: NCT04823897

Phase 1, Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC),
Location: Boston MA, New York NY, Sarasota FL, Columbus OH,
Sponsor: Olema Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06784193

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial